JAK — Drug Target
All drugs that target JAK — marketed and clinical-stage. Includes 1 drug classes acting on this target.
Drug classes
Phase 3 pipeline (2)
- Upadacitinib Oral Product · McMaster University · JAK inhibitor · Immunology
Upadacitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK enzymes, which play a key role in the inflammatory response. - baricitinib treatment · University Hospital, Bordeaux · JAK inhibitor · Immunology
Baricitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK enzymes, which play a role in inflammation.
Phase 2 pipeline (6)
- ATI-50002 topical solution · Aclaris Therapeutics, Inc. · JAK inhibitor · Dermatology
ATI-50002 topical solution is a small molecule that targets the Janus kinase (JAK) pathway. - CP-690,550 Ointment 2 · Pfizer · JAK inhibitor · Immunology
CP-690,550 is a Janus kinase (JAK) inhibitor. - ARQ-154 · Arcutis Biotherapeutics, Inc. · JAK inhibitor · Dermatology
ARQ-154 is a topical Janus kinase (JAK) inhibitor. - AN2728 Topical Ointment, 2% BID · Pfizer · JAK inhibitor · Dermatology
AN2728 is a topical ointment that targets the Janus kinase (JAK) pathway to modulate inflammation. - AN2728 Topical Ointment, 0.5% BID · Pfizer · JAK inhibitor · Dermatology
AN2728 is a topical ointment that targets the Janus kinase (JAK) pathway to modulate inflammation. - CGB-500 Ointment with 1% tofacitinib · CAGE Bio Inc. · JAK inhibitor · Immunology
Tofacitinib is a Janus kinase (JAK) inhibitor that suppresses the activity of JAK enzymes, which play a key role in the signaling of cytokines involved in inflammation.